|
|
|
01 Sep 2010 |
Concordia Pharmaceuticals, Inc. Signs First Licensing Agreement with Ono Pharmaceutical Co, Ltd. for Salirasib
|
4 |
|
30 Aug 2010 |
Eisai Announces Extension of FDA Review of Drug Application for Investigational Agent Eribulin Mesylate
|
6 |
|
27 Aug 2010 |
Genentech Receives Refuse to File Letter from FDA for T-DM1
|
13 |
|
27 Aug 2010 |
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
|
5 |
|
26 Aug 2010 |
Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate in Metastatic Melanoma Patients in the New England Journal of Medicine
|
5 |
|
26 Aug 2010 |
Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate in Metastatic Melanoma Patients in the New England Journal of Medicine
|
5 |
|
24 Aug 2010 |
Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
|
8 |
|
24 Aug 2010 |
BioAlliance Pharma Announces the Launch of Oravig on the US Market by Its Commercial Partner, Strativa/Par Pharmaceutical
|
7 |
|
24 Aug 2010 |
Celsion Receives Fast Track Designation for ThermoDox Development Program to Treat Primary Liver Cancer
|
7 |
|
24 Aug 2010 |
Cellceutix Closing in on Human Trials with Kevetrin(TM) for Drug-Resistant Cancers as the Company Reports Progress on Toxicity Studies
|
8 |
|
24 Aug 2010 |
Synta Announces First Patient Treated in Clinical Trial of STA-9090 in Combination with Docetaxel in Solid Tumors
|
9 |
|
24 Aug 2010 |
GSK European Commission amends licence for Cervarix
|
6 |
|
23 Aug 2010 |
Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)
|
11 |
|
23 Aug 2010 |
EpiCept Corporation Receives Refusal to File Letter from US FDA on Ceplene New Drug Application
|
10 |
|
23 Aug 2010 |
BIND Biosciences Presents Preclinical Data for Novel Nanomedicine, BIND-014, at American Chemical Society National Meeting
|
10 |
|
20 Aug 2010 |
REVLIMID Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
|
6 |
|
20 Aug 2010 |
REVLIMID Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
|
6 |
|
19 Aug 2010 |
Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
|
9 |
|
19 Aug 2010 |
SRI International to Advance Clinical Development of TAS-108, a Late-Stage Breast Cancer Drug
|
9 |
|
18 Aug 2010 |
Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma
|
10 |
|
18 Aug 2010 |
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
|
7 |
|
18 Aug 2010 |
Advaxis Completes Dosing Vanguard Group in Phase II Cervical Dysplasia (CIN) Study
|
8 |
|
18 Aug 2010 |
Clavis Pharma ASA (NO) - Clavis Pharma recruits first patient in pivotal Phase III study of elacytarabine in late-stage acute myeloid leukaemia
|
11 |
|
17 Aug 2010 |
MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
|
8 |
|
16 Aug 2010 |
EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
|
13 |
|
16 Aug 2010 |
Morphotek, Inc. Announces Initiation of a Phase I Study for MORAb-028, an IgM-Type Monoclonal Antibody, in Patients with Advanced Melanoma
|
11 |
|
13 Aug 2010 |
Astex Therapeutics and Multiple Myeloma Research Consortium Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma
|
10 |
|
12 Aug 2010 |
AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma
|
13 |
|
11 Aug 2010 |
Biotest AG: Development of BT-062 makes further progress with start of a new clinical trial
|
11 |
|
11 Aug 2010 |
Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial
|
12 |
| |
|
Results 1 - 30 of 4328 |
